For Scientists

At Bavarian Biotech, we support academic researchers in oncology and drug development by providing specialized High-Affinity Probe (HAP) services for preclinical research and translational studies. Our technology allows for precise, in situ quantification of therapeutic binding site availability, offering new possibilities for researchers working with preclinical models, patient derived xenografts, and novel drug candidates.

Target Validation & Drug Development

• Use HAP-based assays to quantify and visualize drug-target interactions in cell lines, patient-derived xenografts (PDX), and organoid models.
• Compare HAP staining vs. conventional IHC to determine true therapeutic target accessibility.

Preclinical Model Optimization

• Evaluate how well your tumor models mimic human drug-target interactions using HAP staining.
• Assess heterogeneity in target expression across different tumor models to select the most relevant system for drug testing.

Explore Tumor Heterogeneity 

• Spatially visualize which tumor populations are engaged by your drug of interest.
• Create a rationale for drug combination or therapy sequencing by exploring several drug target binding sites in the same slide using our HAP-multiplex solutions.

Predicting Drug Efficacy & Resistance Mechanisms

• Investigate whether your drugs of interest effectively bind their targets on primary patient tissue to explore potential clinical benefits in diverse patient populations.
• Identify potential mechanisms of drug resistance due to target downregulation or other therapy dynamic biomarkers.

Companion Biomarker Discovery

• Use HAP-based profiling to identify potential predictive biomarkers for drug response in preclinical settings.
• Validate biomarker expression across tumor models and primary tumor tissues to support clinical translation.